Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
11 October 2019Website:
http://www.vir.bioNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 21:34:39 GMTDividend
Analysts recommendations
Institutional Ownership
VIR Latest News
Vir Biotechnology (VIR) rises on upbeat data from its phase II study evaluating tobevibart and elebsiran for the treatment of people living with chronic hepatitis delta.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company's Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer. Dr. Eisner comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In.
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company's chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will hig.
Vir Biotechnology, Inc. (NASDAQ: VIR) Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET featured company executives Sasha Damouni Ellis, Marianne De Backer, Carrie Huang, and Sung Lee. Conference call participants included Gena Wang, Paul Choi, Alec Stranahan, Phil Nadeau, Patrick Trucchio, Rosa Chen, Joseph Stringer, Eric Joseph, and Michaels Ulz. The call was moderated by the operator who greeted everyone.
Vir Biotechnology, Inc. (VIR) reported a quarterly loss of $0.48 per share, which was lower than the expected loss of $0.99 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $1.06 per share reported in the same quarter last year.
The consensus price target hints at an 186.4% upside potential for Vir Biotechnology, Inc. (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $0.76 per share a year ago.
After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2023 Results Conference Call November 2, 2023 4:30 PM ET Company Participants Sasha Damouni Ellis - Executive Vice President, Chief Corporate Affairs Officer Marianne De Backer - Chief Executive Officer Phil Pang - Chief Medical Officer Sung Lee - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Patrick Trucchio - H. C. Wainwright Nik Gasic - Leerink Partners Eva Privitera - TD Cowen Joseph Stringer - Needham & Company Operator Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call.
Vir Biotechnology Inc has faced a tough year so far, with shares declining by 54% year-to-date. Much of the company's underperformance is attributed to unimpressive results from both influenza A and hepatitis B (HBV) trials, Bank of America wrote in a new note.
What type of business is Vir Biotechnology?
Vir Biotechnology, Inc. is an American clinical immunology company. Registered in 2016 in the state of Delaware. Headquarters are located in San Francisco, California. The company specializes in developing methods based on a combination of immune responses and advanced technologies for the treatment and prevention of serious diseases such as hepatitis B or HBV, influenza A, severe acute respiratory syndrome, coronavirus 2 or SARS-CoV-2, human immunodeficiency virus or HIV, and tuberculosis. Drug candidates are developed on four technological platforms focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or miRNA, through internal development, collaborations, and acquisitions.
What sector is Vir Biotechnology in?
Vir Biotechnology is in the Healthcare sector
What industry is Vir Biotechnology in?
Vir Biotechnology is in the Biotechnology industry
What country is Vir Biotechnology from?
Vir Biotechnology is headquartered in United States
When did Vir Biotechnology go public?
Vir Biotechnology initial public offering (IPO) was on 11 October 2019
What is Vir Biotechnology website?
https://www.vir.bio
Is Vir Biotechnology in the S&P 500?
No, Vir Biotechnology is not included in the S&P 500 index
Is Vir Biotechnology in the NASDAQ 100?
No, Vir Biotechnology is not included in the NASDAQ 100 index
Is Vir Biotechnology in the Dow Jones?
No, Vir Biotechnology is not included in the Dow Jones index
When does Vir Biotechnology report earnings?
The next expected earnings date for Vir Biotechnology is 02 August 2024